Lipotek is an Australian clinical-phase biotechnology company with a focus on the development of novel vaccines and immunotherapies.

There is an undeniable need for technological solutions for prophylactic and therapeutic vaccination against pathogens, cancer and other diseases that have limited or no treatment options.

Lipotek is expanding its activities to demonstrate the versatility of its Lipovaxin platform for non-vaccine applications.
more news...Lipotek is dedicated to developing versatile antigen delivery modules that facilitate dendritic cell (DC) targeting and activation in vivo. DCs are antigen presenting cells that act as key regulators of the immune system. Depending on the antigen environment encountered, they exert either immunogenic or tolerogenic effects. Lipotek's approach to vaccine design is therefore to ensure that antigens are delivered to DCs, with simultaneous activation of DCs using cytokines and/or Toll-like receptor (TLR) ligands.

Our proprietary technologies (Lipovaxin and Lipokel) can deliver various types of antigenic cargo specifically to DCs, with improved immunogenicity, without the need for antigen modification or formulation with traditional adjuvants. These versatile approaches enable the rapid and efficient development of novel vaccines and immunotherapeutic products.

Lipovaxin liposomes are versatile. When combined with a suitable targeting ligand these delivery vehicles can act as highly specific delivery agent for a wide range of molecules.